A Phase 3 interventional study of Mometasone Furoate Nasal Spray, 50 mcg and Nasonex Nasal Spray, 50 mcg in Seasonal Allergic Rhinitis, sponsored by Amneal Pharmaceuticals, LLC. Completed at 10 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-11-02.
Sponsored by Amneal Pharmaceuticals, LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · United States.
Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, this one is the 17th largest by enrollment of the 101 interventional ones that give a count, is one of 6 that started in 2014, is one of 47 in phase 3, and was the 90th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →1 of the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States is open now. Recruiting first, the newest first:
Polyrizon Ltd. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 24 · Phase 3 48 · Phase 4 18
First in 2001; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 811 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 446 across the 101 interventional studies, 92 across the 5 observational. Of the 100 that completed or were terminated, 56 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 107 have an industry lead sponsor. The 10 most frequent:
This study is registered under Amneal Pharmaceuticals, LLC, one of the names counted as Amneal Pharmaceuticals, Inc.. Under that name alone:
Amneal Pharmaceuticals, LLC is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Amneal Pharmaceuticals, Inc. has 1 study filed under Rhinitis, Allergic, Seasonal — fewer than ten, so there is no comparison to draw.
1 of the studies in Rhinitis, Allergic, Seasonal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07588672Polyrizon Ltd.Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis | 2027-07-15 |
Add it to your calendar (.ics) → With an account.
Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the therapeutic equivalence of the lest formulation of Mometasone Furoate Nasal Spray, 50 mcg to the marketed formulation NASONEX® (mometasone furoate monohydrate) Nasal Spray, 50 mcg/actuation in patients with seasonal allergic rhinitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
of the randomization visit.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mometasone Furoate Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
Drug: Mometasone Furoate Nasal Spray, 50 mcg
Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
Drug: Nasonex Nasal Spray, 50 mcg
Placebo of Mometasone Furoate Nasal Spray. 4 actuations per day for 14 days.
Drug: Placebo Nasal Spray
a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
a metered-dose, manual pump spray unit containing an aqueous suspension
Change from Baseline rTNSS
Change from baseline in average AM/PM reflective Total Nasal Symptom Score (rTNSS) over Days 1 to 14
Time frame: Days 1 - 14
Total Nasal Symptom Score (TNSS)
The sum of patient-rated severity scores for four allergy symptoms : runny nose, nasal congestion, itchy nose, and sneezing based on a 4-point scale.
Time frame: Days 1 - 14
Change in Baseline iTNSS
Change from baseline in average instantaneous Total Nasal Symptom Score (iTNSS) over Days 1 to 14.
Time frame: Days 1 - 14
The record gives a start of Jan 2014, a primary completion of Mar 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rhinitis, Allergic, Seasonal →